What Your Peptide Product Copy Tells a Payment Underwriter

For a research-use peptide store, your product copy is evidence. A high-risk payment underwriter reads your site to decide what you actually sell. If your pages describe dosing, results in people, or what a compound treats, they contradict the research-use business on your application. That gap is the problem. You can't fix it with a disclaimer at the bottom of the page. You fix it by writing the whole site as the business you say you are.

This is a rewrite of an earlier post on the same subject. It's built from the compliance work in the peptide stores we've built and maintain. One thing up front: none of the stores we've built has had its payments frozen. We don't credit that to copy alone, because processors weigh many things. But copy is the part of the file you fully control.

None of this is legal advice. Which wording your business can use is a question for a lawyer who knows this category. What follows is how we build sites so that question is easy to answer.

Why the payment provider reads your website

Mainstream payment providers set up most merchants automatically. This category is different. Stripe's prohibited-business list includes "incorrectly labeled research chemicals" and "pseudo-pharmaceuticals or nutraceuticals that are not safe or make harmful claims" (Stripe: Prohibited and restricted businesses). In practice, research-use peptide stores end up with high-risk merchant accounts that a person underwrites, or they skip card processing entirely.

A human underwriter compares two documents: your application and your website. The application says laboratory research supply. If the product pages say "accelerates healing," list a dosing schedule, or show before-and-after photos, the website describes a different business. Applying under a softer category than the one you really operate in is worse still. Processors treat it as misrepresentation, and an account closed for cause can be added to Mastercard's MATCH list, a shared record other processors check before approving you. We cover the processor side in more depth on our sister site, Sell Peptides Online.

The five kinds of wording we screen out

Across our research-use builds, the banned-word lists sort into the same five groups:

1. Dosing, route and human use. Doses and units per day, "inject," "administer," "subcutaneous," syringes, "cycle," "stack," "protocol," and step-by-step mixing instructions written for a person.
2. Outcome and benefit claims. Weight loss, fat loss, muscle growth, healing, recovery, anti-aging, longevity, libido, sleep, cognition, tanning, skin results.
3. Medical and therapeutic language. Treat, therapy, cure, prevent, diagnose, patient, prescription.
4. Grade and comparison claims. "Pharmaceutical grade," "clinically proven," "FDA approved," "an alternative to" a named brand-name drug, or any brand-name drug used to sell the product.
5. Consumer-retail framing. "Your results," "your journey," "transform," testimonials, and before-and-after photos. Syringe and injection-site images belong here too, along with "supplement" or "wellness" used as a selling point.

The groups matter more than any single word. A disclaimer can say "not for human consumption," but if the same page says "your results," the page is arguing with itself.

A real rewrite: 838 flagged terms down to 98

One established store we work with had product pages that had grown over years: dosing-reference sections, research summaries phrased around human outcomes, and condition names in the copy. We scanned the catalog, rewrote the product pages from approved copy, and scanned again.

Across 23 rewritten product pages, flagged terms fell from 838 to 98. Only 11 of those 98 were left in the rewritten copy, all of them harmless matches. The other 87 sat in research citations we hadn't touched yet.

The citations got their own pass. Of 175 citations across 20 pages, we removed 111: 50 framed the compound as a therapy, 40 described a desired outcome, 17 cited human trials, and 4 described how it is administered. Citing a human trial on a product page is a quiet way of implying human use, even when every sentence around it is careful.

The scan also caught 57 sentences of internal editing notes that would otherwise have gone live with the new copy. That's a different kind of risk, but the same check caught it.

Names are copy too

On another build, the product's name was the problem. It was named for what it does to the body, and that description of function is a claim on its own. We renamed it for what it is used for. Then we added the old names to a banned list, so the build fails if they ever come back.

Renaming has limits, and the project notes say so plainly. A name doesn't change what the product sits beside in the catalog, or what the rest of the site implies about how it's used. What was left of that decision went to the client's counsel, which is where it belonged.

Build the check into the site, not into a memory

A wording rule that lives in someone's head only lasts until the next product upload or blog post. The more reliable pattern is to make the check part of the site:

• One shared list. The same list of banned words is used by the site scanner and its tests, so they never disagree.
• Whole-word matching, with an allow list for disclaimers. "Not for human consumption" has to pass, and "for human consumption" has to fail. The allow list exempts whole disclaiming sentences, never bare words.
• Scan the rendered pages, not just the source files. Copy arrives from product databases, templates and plugins. Check what the visitor actually sees.
• Scan the emails too. Order confirmations and shipping notices are part of the same file an underwriter can see. A careful product page means little if the shipping email reads like a consumer brand.
• Fail the build where you can. On at least one of our builds, a banned product name stops the site from deploying at all. That is the strongest version of the check.
• Review blog posts, don't just pattern-match them. Our blog tooling sends borderline posts to a person instead of rejecting them automatically. It hard-fails only when a single sentence combines a dose, a route of administration and an instruction.

Payments: the copy and the checkout should agree

Copy is half of it. The other half is how the store takes money. Across our builds the setups differ, and each one is chosen deliberately:

• No card checkout at all. The store takes orders by quote, inquiry or order sheet, then invoices for ACH, wire, or a payment app. On these sites, the copy that explains why there is no card option turns out to be some of the most important on the page.
• Cards taken by phone or terminal, alongside bank payments, for wholesale buyers who order on account.
• A live card checkout through a high-risk gateway, with bank and app payments offered as alternatives.

Whichever you run, the checkout has to tell the same story as the product page. That's also why we never put a research-use store on a mainstream processor's standard account, and never apply under a different category to get approved.

A ten-minute self-check

1. Read one product page as an underwriter would. Ignore the disclaimer. Does the rest of the page describe laboratory supply, or a result in a person?
2. Search your own site for "dose," "inject," "results," "before and after," and the brand name of any prescription drug.
3. Check what's around the product. Look at related products, blog links, and the research citations under the description.
4. Read your order confirmation and shipping emails against the same standard.
5. Compare your website to your merchant application. Do they describe the same business, in the same words?

If the answers are uncomfortable, the fix is usually a copy and catalog project, not a rebuild. We do that work on WooCommerce stores and custom builds. We also connect the payment side so that it, the copy and the records all match. For the rest of what a compliant research-use site needs, see peptide website design. Gates are a separate topic, covered in how to build an age gate Google can still read.